El Hadadi et al., 2021 - Google Patents
Comorbidities and Complications among Pemphigus patients: a retrospective cohort studyEl Hadadi et al., 2021
View PDF- Document ID
- 8540687456335420491
- Author
- El Hadadi F
- Mezni L
- Senouci K
- Meziane M
- Benzekri L
- Ismaili N
- Publication year
- Publication venue
- Journal of Investigative Dermatology
External Links
Snippet
Pemphigus is a chronic bullous disease with a poor prognosis, especially in case of a mucocutaneous involvement. Due to immune disturbance and skin barrier deficiency, complications are frequent. We performed a retrospective cohort study based on medical …
- 241000721454 Pemphigus 0 title abstract description 12
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US12258377B2 (en) | Anti-tumour response to modified self-epitopes | |
Huijbers et al. | Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders | |
Speckmann et al. | X-linked inhibitor of apoptosis (XIAP) deficiency: the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis | |
Singh et al. | Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis | |
Bowcock et al. | Getting under the skin: the immunogenetics of psoriasis | |
Zhou et al. | BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis | |
KR101692080B1 (en) | Novel compositions and methods for the treatment of immune related diseases | |
JP2010518873A (en) | Antagonist anti-OX40 antibodies and their use in the treatment of inflammatory and autoimmune diseases | |
CN104159919A (en) | Methods of treatment using an antibody against interferon gamma | |
Hashimoto et al. | Pathogenesis of epidermolysis bullosa acquisita, an autoimmune subepidermal bullous disease | |
KR20170018814A (en) | Binding molecules specific for il-21 and uses of thereof | |
Liu et al. | Novel roles of the Tim family in immune regulation and autoimmune diseases | |
JP2021528965A (en) | Immunodominant proteins and fragments in multiple sclerosis | |
Zheng et al. | Characteristics of IgG subclasses and complement deposition in BP 230‐type bullous pemphigoid | |
Inagaki-Ohara et al. | Suppressor of cytokine signalling 1 in lymphocytes regulates the development of intestinal inflammation in mice | |
Ferhat et al. | The newly engineered monoclonal antibody ON104, targeting the oxidized Macrophage Migration Inhibitory Factor (oxMIF), ameliorates clinical and histopathological signs of collagen-induced arthritis | |
El Hadadi et al. | Comorbidities and Complications among Pemphigus patients: a retrospective cohort study | |
US20200103416A1 (en) | SNX9 as a novel biomarker for chronic inflammation and associated immunosuppresion and a new regulator of T cell receptor expression and function | |
Okumura et al. | Autoantibodies reactive to PEP08 are clinically related with morbidity and severity of interstitial lung disease in connective tissue diseases | |
US20140037659A1 (en) | Snx9 as a novel biomarker for chronic inflammation and associated immunosuppresion and a new regulator of t cell receptor expression and function | |
Englebert et al. | The CD27/CD70 pathway negatively regulates visceral adipose tissue-resident Th2 cells and controls metabolic homeostasis | |
JP2023538975A (en) | How to reduce maternal autoantibodies | |
Chan | Review on pathogenesis of pemphigus | |
Ramcke et al. | Autoreactive Tfh cells drive induction of BP-like skin disease | |
Poddubnyy et al. | OP0097 Cigarette smoking predicts radiographic progression in the spine in patients with axial spondyloarthritis in a dose-dependent manner |